Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

Quality of care for heart patients does not improve in first year of ACO participation
Researchers tracked patient outcomes through the use of 15 performance measures related to hypertension, coronary artery disease, heart failure and atrial fibrillation.
Key takeaways from ACC.25: Advances in cardiovascular science
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.
Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’
Researchers still think patients should receive an injectable version of semaglutide when possible, but new data out of ACC.25 confirm that an oral formulation of the drug is associated with significant benefits.
‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes
Patients who present with type 2 diabetes and PAD often face substantial mobility issues. According to new data presented at ACC.25, however, treatment with semaglutide could represent a major step forward for this high-risk population.

The pandemic's impact on statin prescriptions

The analysis, published in Circulation: Cardiovascular Quality and Outcomes, included more than 20,000 patient encounters.

Web-based resource helps consumers make key decisions about statin use

Researchers tracked data from 500 participants who completed a web-based evaluation in their home.

ASCVD events, death more likely when patients ignore statin recommendations

These findings have important clinical implications for ASCVD prevention.

Edoxaban comparable to VKAs for treating AFib after TAVR

Researchers shared their findings at ESC Congress 2021 and in the New England Journal of Medicine.

Rivaroxaban limits adverse limb and cardiovascular events in surgically treated PAD patients

Rivaroxaban was associated with more bleeding than a placebo, researchers observed, but the overall incidence of such events was still low.

Statin use prior to hospitalization linked to lower COVID-19 mortality

The trend is particularly noticeable in patients with a history of CVD or hypertension.

Chronic liver disease associated with worse PCI outcomes

Researchers tracked data from more than 54,000 adult patients with CLD who underwent PCI from 2004 to 2015.

FDA pushes for statin warnings to be updated

It has long been believed that patients should not take statins while they are pregnant. Now, however, the FDA is emphasizing that there are certain exceptions to that rule.

Pharmaceutics

Quality of care for heart patients does not improve in first year of ACO participation

Key takeaways from ACC.25: Advances in cardiovascular science

Dapagliflozin improves outcomes for elderly TAVR patients with heart failure

Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’

‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes